eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 10

Clinical research
A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers

Ke-Jun Liu, Zhong-Zhen Guan, Ying Liang, Xu-Qing Yang, Jin Peng, He Huang, Qing-Xiang Shao, Meng-Zhao Wang, Yun-Zhong Zhu, Chang-Ping Wu, Shao-Bin Wang, Jian-Ping Xiong, Yu-Xian Bai, Shi-Ying Yu, Yang Zhang, Xiao-Hua Hu, Ji-Feng Feng, Shi-Xiu Wu, Shun-Chang Jiao, Cai-Cun Zhou, Jie Wang, Hai-Ying Wu

Arch Med Sci 2014; 10, 4: 717–724
Online publish date: 2014/08/29
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Introduction: The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC).

Material and methods: In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1 : 1) to receive dicycloplatin 450 mg/m2 or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m2 (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. The primary endpoint was response rate. Secondary endpoints included progression-free survival (PFS), overall survival (OS) and adverse events.

Results: The response rates for the D + P and C + P arm were 36.44% and 30.51%, respectively (p = 0.33). The median PFS was 5.6 months in the D + P arm and 4.7 months in the C + P arm (p = 0.31). The median OS was 14.9 months for D + P and 12.9 months for C + P (p = 0.37). Adverse events in the two arms were well balanced. The most common grade 3/4 adverse event was hematologic toxicity.

Conclusions: Patients treated with D + P had similar response and survival rates to those treated with C + P, and toxicities of both treatments were generally tolerable.

dicycloplatin, platinum derivative, first-line therapy, non-small-cell lung cancer (NSCLC), phase II study

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe